UFGirl wrote:Hi! I am a longtime lurker/reader but haven't posted. I have read through a lot of the hormone replacement therapy threads including Stavia's report on the San Diego Meetup from 2017 and was just wondering if Ann Hathaway's lecture from this event is still the most recent protocol/science on HRT and where we are as a group? Thanks! This forum has really been incredible as someone who has multiple relatives who have had Alzheimer's including my mom who just recently died.
UFGirl wrote:Hi RenLets,
Thanks so much! Can you link me to the HRT thread? I thought this was the one. Thanks again!
Age and response to HT
The impact of age on HT response is illustrated in two studies. In a randomized longitudinal study of postmenopausal women with a mean age of 57.7 year, impact of HT on an indicator of aging, telomere length, was investigated [24].
Outcomes of these analyses on a biomarker of aging biology indicated that APOE-e4 carriers had marked telomere
attrition during the 2-year study window which was equivalent to approximately one decade of additional aging compared to non-carriers. Further analyses revealed a modulatory effect of HT on the association between APOE status and telomere attrition. APOE-e4 carriers who continued HT during the 2 year trial sustained telomere length and did not exhibit signs of aging, whereas women who discontinued HT telomere length shortened consistent with accelerated aging [24]. Women who did not carry the APOE4 allele exhibited no protective effect of HT on telomere length [24]. The impact of HT in APOE4 positive women in the Nurses’ Health Study indicated that cognitive function in 70–81 year old APOE4 carriers currently using HT was associated with a slight increase in rate of decline [25]...From a clinical perspective, precision HT is critical to delivering personalized medicine for management of menopausal symptoms and bridging the gap between health span
and life span in postmenopausal women. Achieving precision HT requires inclusion of multiple factors including age,
genetic risk factors, symptomatic phenotype and clinical history
Return to “Prevention and Treatment”
Users browsing this forum: cdamaden and 44 guests